- Trials with a EudraCT protocol (14)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
14 result(s) found for: Hypopharyngeal cancer.
Displaying page 1 of 1.
EudraCT Number: 2020-003474-45 | Sponsor Protocol Number: 74742 | Start Date*: 2023-02-17 |
Sponsor Name:Erasmus University Medical Center | ||
Full Title: The STELLAR trial: Fluorescence-guided surgery in laryngeal- and hypopharyngeal cancer: a feasibility trial | ||
Medical condition: Squamous cell carcinoma of the larynx and hypoharynx | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2008-001354-41 | Sponsor Protocol Number: UCLONCO08-001 | Start Date*: 2008-04-11 | ||||||||||||||||||||||||||
Sponsor Name:Cliniques Universitaires St Luc, Centre du Cancer | ||||||||||||||||||||||||||||
Full Title: Neoadjuvant cetuximab monotherapy followed by surgery in squamous cell carcinoma of head and neck: phase I/II study | ||||||||||||||||||||||||||||
Medical condition: patients with squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx newly diagnosed and eligible for surgery. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-002187-25 | Sponsor Protocol Number: Accrobat | Start Date*: 2007-01-26 |
Sponsor Name:Radiumhemmet, Karolinska University Hospital | ||
Full Title: A multicenter, open label, non-randomised phase II study with induction chemotherapy with Cisplatin and 5-fluorouracil as combined with accelerated radiotherapy and Erbitux for locally advanced unr... | ||
Medical condition: Patient with locally advanced non-resectable squamous cell carcinoma of the head and neck stage III or IV, oral, oropharyngeal, laryngeal or hypopharyngeal cancer, non-resectable. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-003484-23 | Sponsor Protocol Number: Paccis-RCT_2005 | Start Date*: 2010-04-14 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Universitätsklinikum Erlangen, Strahlenklinik insoweit handelnd für den Freistaat Bayern | |||||||||||||||||||||||||||||||||||||||||||
Full Title: Randomised phase-III-trial of simultaneous radiochemotherapy (RCT) of locally advanced head and neck cancer in the stages III and IV A-B: Comparing dose reduced RCT (63.6 Gy) with Paclitaxel/Cispla... | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Head and Neck cancer, Stage III-IV A-B | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-006091-38 | Sponsor Protocol Number: DeLOSII | Start Date*: 2007-05-31 | ||||||||||||||||
Sponsor Name:Universität Leipzig | ||||||||||||||||||
Full Title: Randomisierte Phase II Screeningstudie zum Einsatz einer TP/TPF-Chemotherapie (Kurzinduktion) vor TP/TPF-Induktion, Radiotherapie mit und ohne Cetuximab in der Primärtherapie des nur durch Laryngek... | ||||||||||||||||||
Medical condition: by laryngectomy operable carcinoma of the larynx and the hypopharynx | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) AT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-012225-12 | Sponsor Protocol Number: 64-Cu-ATSM-CC-02/2009 | Start Date*: 2009-09-15 | ||||||||||||||||||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | ||||||||||||||||||||||||||||
Full Title: Role of 64Cu-ATSM PET/CT for the localization of hypoxic areas in head and neck cancer | ||||||||||||||||||||||||||||
Medical condition: head and neck cancer. MEDRA code has not been found. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004603-35 | Sponsor Protocol Number: REACH | Start Date*: 2009-04-28 | |||||||||||||||||||||
Sponsor Name:University of Heidelberg | |||||||||||||||||||||||
Full Title: Radiotherapy (IMRT), Erbitux And Chemotherapy For Unresectable Carcinomas Of Head and Neck. REACH-Study | |||||||||||||||||||||||
Medical condition: Histologically confirmed locally advanced (stage III or IV), non-metastatic squamous cell carcinoma of oro-, hypopharynx or larynx (T2-4, NX, M0). | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-003833-24 | Sponsor Protocol Number: AGMT_HNO_PN | Start Date*: 2016-06-30 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:AGMT – Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Randomized phase III study: Supplemental parenteral nutrition for patients with locally advanced inoperable tumors of the head and neck, receiving definitive radiotherapy with Cetuximab or Cisplatin | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Locally advanced inoperable tumors of the head and neck under definitive radiotherapy with Cetuximab or Cisplatin | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: AT (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-003226-33 | Sponsor Protocol Number: 0480 | Start Date*: 2018-09-13 | |||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Dean of the Medical Faculty of the Friedrich-Alexander University Erlangen-Nürnberg Prof. Dr. Markus Neurath | |||||||||||||||||||||||||||||||||||||||||||
Full Title: First-line treatment of locally advanced HNSCC with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+ T cell infiltration (CheckRad-CD8) | |||||||||||||||||||||||||||||||||||||||||||
Medical condition: Locally advanced head and neck squamous cell carcinoma (HNSCC) | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-004052-11 | Sponsor Protocol Number: UC-HNG/1909 | Start Date*: 2020-07-08 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:UNICANCER | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A phase II trial assessing Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in a pre-operative setting for resectable and untreated head and neck squamous cell carcinoma | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Histologically or cytologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx, previously untreated, with indication of primary surgery. Patients with a di... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: FR (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-013438-26 | Sponsor Protocol Number: 135 | Start Date*: 2010-08-24 |
Sponsor Name:Karolinska University Hospital | ||
Full Title: A multicentre, open label, randomised phase II study with docetaxel (Taxotere®), cisplatin and 5-fluorouracil as induction chemotherapy, combined with hyperfractionated radiotherapy and cetuximab ... | ||
Medical condition: Patients with non-resectable stage III-IV head and neck cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-006120-36 | Sponsor Protocol Number: N07CRH | Start Date*: 2009-01-07 |
Sponsor Name: | ||
Full Title: Phase I/II Study of Combined Treatment with AT-101, Cisplatin and Radiotherapy in Patients with Locally Advanced Head and Neck Cancer | ||
Medical condition: advanced HNSCC | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2006-002667-33 | Sponsor Protocol Number: 24051 | Start Date*: 2007-06-18 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer | |||||||||||||
Full Title: Phase I/II study on induction chemotherapy followed by chemoradiation with or without lapatinib, a dual EGFR/ErbB2 kinase inhibitor, in patients with locally advanced resectable larynx and hypophar... | |||||||||||||
Medical condition: locally advanced resectable larynx and hypopharynx squamous cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004161-68 | Sponsor Protocol Number: AG013-ODOM-201 | Start Date*: 2018-10-31 | |||||||||||
Sponsor Name:Oragenics, Inc. | |||||||||||||
Full Title: A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically-applied AG013 for the attenuation of oral mucositis in subjects with cance... | |||||||||||||
Medical condition: Oral mucositis (OM) induced by chemoradiation therapy (CRT) used for the treatment of head and neck cancers (HNC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Prematurely Ended) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
